Core Viewpoint - ZimVie Inc. reported a net sales decrease of 5.2% for Q1 2025, but showed significant improvement in net loss and adjusted net income compared to the same period in 2024, indicating a focus on operational efficiency and profitability improvements [2][3][4]. Financial Performance - Net sales for Q1 2025 were $112.0 million, down 5.2% from Q1 2024, with a constant currency decrease of 4.1% [2][28]. - The net loss for Q1 2025 was $(2.6) million, an improvement of $8.9 million from a net loss of $(11.5) million in Q1 2024, resulting in a net loss margin of (2.3%), up 740 basis points from (9.7)% in Q1 2024 [3][4]. - Adjusted net income for Q1 2025 was $7.4 million, an increase of $5.2 million compared to Q1 2024 [3][4]. Earnings Per Share - Basic and diluted EPS for Q1 2025 were $(0.09), while adjusted diluted EPS was $0.27 [4][29]. Adjusted EBITDA - Adjusted EBITDA for Q1 2025 was $17.6 million, representing 15.7% of net sales, an increase of $5.1 million or 520 basis points from Q1 2024 [4][35]. Full Year Guidance - For the full year 2025, ZimVie projects net sales between $445 million and $460 million, adjusted EBITDA between $65 million and $70 million, and adjusted EPS between $0.80 and $0.95 [5]. Operational Focus - The company emphasizes a strong focus on execution and operational diligence to maintain its leading position in the dental market through innovation and education [2][8].

Company Overview - ZimVie Inc. is a global leader in the dental market, focusing on life sciences and offering a comprehensive portfolio of products for dental tooth replacement and restoration procedures [2][3] - The company is headquartered in Palm Beach Gardens, Florida, and operates additional facilities worldwide [2] Financial Results Announcement - ZimVie will report its financial results for the first quarter of 2025 after market close on May 8, 2025 [1] - A conference call will be hosted by company management at 4:30 p.m. Eastern Time on the same day [1] Conference Call Details - Interested participants can register online to listen to the conference call, with a recommendation to register more than 15 minutes before the start [2] - A replay of the webcast will be available on the investor section of ZimVie's website [2]

Core Viewpoint - ZimVie Inc. has launched its Immediate Molar Implant System in the United States, enhancing its existing TSX and T3 PRO Implant systems to address the complexities of molar tooth restoration, thereby reducing treatment times and improving patient outcomes [1][4]. Group 1: Product Features - The Immediate Molar Implant System includes specially engineered instrumentation that simplifies site preparation during molar extraction, making the procedure more controlled and predictable [2]. - The system features optimized wide-diameter implants that enhance primary stability and potentially reduce the risk of peri-implantitis by up to 20% through proprietary DAE coronal surface technology [2]. - Compared to conventional treatment protocols, the Immediate Molar Implant System allows for restoration in half the time, streamlining the overall treatment process [3]. Group 2: Company Commitment - The launch of the Immediate Molar Dental Implant System represents a significant milestone in ZimVie's commitment to advancing dental technology, aiming to provide shorter and more cost-effective treatment options while ensuring predictable and lasting outcomes for patients [4]. - ZimVie has a history of developing products like the TSX and T3 PRO Implants, which are designed for immediate extraction and loading protocols, ensuring placement predictability and primary stability [5][8]. Group 3: Market Position - ZimVie is positioned as a global leader in the dental implant market, focusing on comprehensive solutions for dental tooth replacement and restoration procedures, with a commitment to improving clinical science and technology [10].

Company Overview - ZimVie Inc. is a global leader in the dental market, focusing on life sciences and providing a comprehensive portfolio of products for dental tooth replacement and restoration procedures [2] - The company is headquartered in Palm Beach Gardens, Florida, and operates additional facilities worldwide [2] - ZimVie aims to enhance smiles, function, and confidence through its offerings, which include dental implants, biomaterials, and digital workflow solutions [2] Upcoming Events - ZimVie management will participate in the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025, at 3:00 p.m. Eastern Time [1] - A live webcast and archived recording of the event will be available on ZimVie's investor website [1]

PALM BEACH GARDENS, Fla., March 13, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced upcoming changes to the Company's Board of Directors, including: Non-Executive Chair David King will not stand for reelection as a director upon the expiration of his current term at the Company's annual meeting of shareholders on May 7, 2025.President and CEO Vafa Jamali will be appointed Chairman of the Board effective as of May 7, 2025.Direc ...

Dentsply Sirona XRAY and ZimVie Inc. ZIMV show below-market growth and have no meaningful upside, according Needham analysts.What Happened: Needham downgraded the two dental companies to Hold.ZimVie reported adjusted EPS of 27 cents, beating the consensus of 26 cents. The company’s sales of $111.52 million fell below the consensus of $113.4 million.Dentsply Sirona, meanwhile, reported fourth-quarter adjusted earnings per share of 26 cents. It missed the street view of 43 cents. Quarterly sales of $905 milli ...

ZimVie Inc. (NASDAQ:ZIMV) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations Vafa Jamali - President & Chief Executive Officer Richard Heppenstall - Chief Financial Officer Conference Call Participants David Saxon - Needham & Company Kevin Caliendo - UBS William McMahon - Barclays Operator Good afternoon and welcome to ZimVie's Fourth Quarter 2024 Earnings Conference Call. Currently, all participants are in a listen-only mode. We'll be facili ...

A Global Dental Leader February 2025 1 Forward-Looking Statements and Non-GAAP Measures Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This presentation contains forward-looking statements within the meaning of federal securities laws, including, among others, any statements about our expectations, plans, intentions, strategies, or prospects. We generally use the words "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides, ...

Pricing and Financial Pressures - The company is facing pricing pressures due to cost containment measures in the U.S. and other countries, including a volume-based procurement program in China that resulted in unsuccessful bids[96] - Group purchasing organizations are negotiating pricing arrangements, which may limit the company's ability to sell products to affiliated members if not selected[98] - The company has experienced downward pressure on product pricing and other effects of healthcare reform in international markets, which could adversely affect its financial condition and cash flows[99] - Inflation has increased the overall cost structure, potentially affecting liquidity and financial condition[120] - A 10% price change in raw material commodities would not have a material effect on the company's consolidated financial position, results of operations, or cash flows[260] Debt and Financial Obligations - The company incurred $595.0 million in floating rate indebtedness and prepaid $275.0 million on the term loan, with $221.9 million outstanding as of December 31, 2024[108] - The company has $221.9 million of floating rate debt, and a hypothetical 100 basis points increase in SOFR would raise annual interest expense by $2.2 million[261] - The company does not expect to pay cash dividends for the foreseeable future, as it intends to retain future earnings for business operations and expansion[169] Inventory and Supply Chain Risks - The company is exposed to risks of excess and obsolete inventory, which may adversely impact cash flow and liquidity[116] - The company has entered into supply contracts for raw materials with terms of 12 to 24 months to mitigate commodity price fluctuations[260] International Operations and Currency Risks - Approximately 41% of the company's net sales in 2024 were derived from international markets, indicating a significant reliance on global operations[124] - A significant portion of foreign revenues is generated in Europe and Japan, making the company vulnerable to currency exchange rate fluctuations[117] - The company is exposed to foreign currency exchange rate risks primarily with Euros, Japanese Yen, Canadian Dollars, and Swiss Francs, and manages this risk through derivative financial instruments[259] Regulatory and Compliance Challenges - The company is subject to income taxes in the U.S. and various foreign jurisdictions, with ongoing audits that could materially affect financial statements[121] - The company is subject to stringent FDA regulations for medical devices, which can delay product approvals and impact financial results[131] - Compliance with the EU MDR, effective since May 2021, requires significant expenses and could delay marketing approvals for products in the EU[135] - The company is exposed to healthcare fraud and abuse laws, which could result in substantial penalties and affect business operations[137] - Data privacy and security laws, including the EU GDPR, impose significant compliance costs and potential liabilities for the company[142] - Compliance with new or changing laws related to data protection could result in substantial civil and/or criminal penalties, adversely impacting the business and financial condition[144] Operational and Technological Risks - Implementation of new enterprise resource planning (ERP) systems has caused disruptions, impacting operating results in 2022, with potential for similar issues in 2025 and beyond[100] - The company is increasingly dependent on sophisticated information technology, and failure to maintain or protect information systems could adversely affect operations[146] - Cyber-attack attempts are becoming more frequent and sophisticated, posing risks to business operations and reputation[149] Legal and Environmental Risks - The company bears the risk of warranty claims on products, which could exceed warranty reserves and harm financial condition[150] - Intellectual property rights are crucial for the company, and failure to protect these rights could result in significant monetary damages and impact product sales[151] - The company is involved in various legal proceedings that could result in adverse outcomes, potentially harming financial results[154] - The business involves the use of hazardous materials, and compliance with environmental laws may incur significant costs and restrict operations[156] - Climate change poses risks to operations from natural disasters, which could increase operational costs and impact supply chains[157] Market and Stock Performance - The market price of the company's common stock may be volatile, influenced by various factors including operating results and market conditions[167] - Analysts' research and reports significantly influence the trading market for the company's common stock, and unfavorable reports could lead to a decline in stock price[164] - The company has significant credit risk concentrations in public and private hospitals and dental practices, particularly in Europe, which are subject to government budget constraints[263] Foreign Regulatory and Trade Risks - The company faces risks from changes in foreign regulatory requirements, currency fluctuations, and trade barriers that could increase operating costs[125] - Zimmer Biomet may require indemnification for additional taxes resulting from acquisitions, which could materially impact the company's financial results[162]

Exhibit 99.1 ZimVie Reports Fourth Quarter and Full Year 2024 Financial Results PALM BEACH GARDENS, Florida, February 26, 2025 (GLOBE NEWSWIRE) – ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter and year ended December 31, 2024. Management will host a corresponding conference call today, February 26, 2025, at 4:30 p.m. Eastern Time. "2024 was a transformational year for ZimVie. We became a pure play dental companyand reshaped ou ...